viruses

MDPI

Correction

Correction: Reynard, O.; *et al*. Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication. *Viruses* 2015, 7, 6233-6240

***Viruses* Editorial Office**

MDPI AG, Klybeckstrasse 64, CH-4057 Basel, Switzerland

Received: 9 May 2016; Accepted: 9 May 2016; Published: 18 May 2016

The *Viruses* Editorial Office wishes to notify its readers of corrections in [1].

The authors refer to [2], writing that the experiments were done using 126 mM/kg/day for mouse treatment without side effects. The correct dose used in [2] was 126 µmol/kg/day.

On page 6235, the last sentence of the first paragraph should read: "These data are in line with published reports on the absence of significant toxicity caused by the inhibitor at the concentration below 75–100 M in Madin-Darby canine kidney cells (MDCK), human hepato cellular carcinoma cells (HUH), HepG2 cells or *ex vivo* in human peripheral blood monocytes [13], as well as in a mouse model where NHC was provided up to 126 µmol per kilogram of body weight during five consecutive days without any measurable side effects [13]".

The original Figure 3 was in French and has been replaced by the following:



The manuscript will be updated and the original will remain available on the article webpage. The authors would like to apologize for any inconvenience caused.

References

1. Reynard, O.; Nguyen, X.-N.; Alazard-Dany, N.; Barateau, V.; Cimarelli, A.; Volchkov, V.E. Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication. *Viruses* **2015**, *7*, 6233–6240. [CrossRef] [PubMed]
2. Stuyver, L.J.; Whitaker, T.; McBrayer, T.R.; Hernandez-Santiago, B.I.; Lostia, S.; Tharnish, P.M.; Ramesh, M.; Chu, C.K.; Jordan, R.; Shi, J.; *et al.* Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. *Antimicrob. Agents Chemother.* **2003**, *47*, 244–254. [CrossRef] [PubMed]